US EditionI Spent Months Begging Doctors to Listen—Then I Got a Surprising Diagnosis
UK, JUL 7 – Teplizumab delays insulin need by an average of three years by training the immune system to protect insulin-producing cells, with the first UK adult patient now receiving treatment.
- Hannah Robinson, a 36-year-old dentist from Devon, became the first adult in the UK to receive teplizumab treatment to delay type 1 diabetes.
- She was diagnosed during pregnancy with early-stage type 1 diabetes, a condition caused by the immune system attacking insulin-producing pancreatic cells.
- Teplizumab, approved in the US and currently under evaluation by the UK's NICE, works by reprogramming the body's immune response to protect insulin-producing beta cells, thereby delaying the need for insulin therapy by up to three years.
- Dr Nick Thomas called teplizumab a "really exciting shift" allowing early targeted treatment to alter the immune process and slow insulin dependence progression.
- The treatment brings hope for more people to delay insulin start and underlines the need for early screening and scaled NHS delivery to reach eligible patients.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
All
Left
3
Center
2
Right
1
This spring, Einar Øgrey Brandsdal was diagnosed with ADHD. – I guess I was the only one who didn't know this.
·Kristiansand, Norway
Read Full Article
A "revolutionary" medicine designed to slow the evolution of type 1 diabetes is tested during this period on a limited number of patients in the United Kingdom, reports DPA March.
·Bucharest, Romania
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left3Leaning Right1Center2Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 33%
R 17%
Factuality
To view factuality data please Upgrade to Premium
